209 related articles for article (PubMed ID: 10742298)
1. Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence.
Muscará MN; Vergnolle N; Lovren F; Triggle CR; Elliott SN; Asfaha S; Wallace JL
Br J Pharmacol; 2000 Apr; 129(7):1423-30. PubMed ID: 10742298
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension.
Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F
Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594
[TBL] [Abstract][Full Text] [Related]
3. Alteration of flow-induced dilatation in mesenteric resistance arteries of L-NAME treated rats and its partial association with induction of cyclo-oxygenase-2.
Henrion D; Dechaux E; Dowell FJ; Maclour J; Samuel JL; Lévy BI; Michel JB
Br J Pharmacol; 1997 May; 121(1):83-90. PubMed ID: 9146891
[TBL] [Abstract][Full Text] [Related]
4. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
Muscará MN; McKnight W; Asfaha S; Wallace JL
Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
[TBL] [Abstract][Full Text] [Related]
5. Impairment of smooth muscle function of rat thoracic aorta in an endothelium-independent manner by long-term administration of N(G)-nitro-L-arginine methyl ester.
López RM; Ortíz CS; Ruíz A; Vélez JM; Castillo C; Castillo EF
Fundam Clin Pharmacol; 2004 Dec; 18(6):669-77. PubMed ID: 15548238
[TBL] [Abstract][Full Text] [Related]
6. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2.
Wallace JL; McKnight W; Reuter BK; Vergnolle N
Gastroenterology; 2000 Sep; 119(3):706-14. PubMed ID: 10982765
[TBL] [Abstract][Full Text] [Related]
7. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
8. Renal functional responses to ischaemia-reperfusion injury in normotensive and hypertensive rats following non-selective and selective cyclo-oxygenase inhibition with nitric oxide donation.
Knight S; Johns EJ
Clin Exp Pharmacol Physiol; 2008 Jan; 35(1):11-6. PubMed ID: 18047621
[TBL] [Abstract][Full Text] [Related]
9. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis.
Reddy BS; Hirose Y; Lubet R; Steele V; Kelloff G; Paulson S; Seibert K; Rao CV
Cancer Res; 2000 Jan; 60(2):293-7. PubMed ID: 10667579
[TBL] [Abstract][Full Text] [Related]
10. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Tindall E
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor.
Davies NM; McLachlan AJ; Day RO; Williams KM
Clin Pharmacokinet; 2000 Mar; 38(3):225-42. PubMed ID: 10749518
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 (COX-2) inhibition limits abnormal COX-2 expression and progressive injury in the remnant kidney.
Fujihara CK; Antunes GR; Mattar AL; Andreoli N; Malheiros DM; Noronha IL; Zatz R
Kidney Int; 2003 Dec; 64(6):2172-81. PubMed ID: 14633140
[TBL] [Abstract][Full Text] [Related]
13. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries.
Hennan JK; Huang J; Barrett TD; Driscoll EM; Willens DE; Park AM; Crofford LJ; Lucchesi BR
Circulation; 2001 Aug; 104(7):820-5. PubMed ID: 11502709
[TBL] [Abstract][Full Text] [Related]
14. Chronic cyclooxygenase-2 inhibition does not alter blood pressure and kidney function in renovascular hypertensive rats.
Richter CM; Godes M; Wagner C; Maser-Gluth C; Herzfeld S; Dorn M; Priem F; Slowinski T; Bauer C; Schneider W; Neumayer HH; Kurtz A; Hocher B
J Hypertens; 2004 Jan; 22(1):191-8. PubMed ID: 15106811
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of angiotensin II activity enhanced the antitumor effect of cyclooxygenase-2 inhibitors via insulin-like growth factor I receptor pathway.
Yasumaru M; Tsuji S; Tsujii M; Irie T; Komori M; Kimura A; Nishida T; Kakiuchi Y; Kawai N; Murata H; Horimoto M; Sasaki Y; Hayashi N; Kawano S; Hori M
Cancer Res; 2003 Oct; 63(20):6726-34. PubMed ID: 14583467
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological profile of celecoxib, a specific cyclooxygenase-2 inhibitor.
Yoshino T; Kimoto A; Kobayashi S; Noguchi M; Fukunaga M; Hayashi A; Miyata K; Sasamata M
Arzneimittelforschung; 2005; 55(7):394-402. PubMed ID: 16080279
[TBL] [Abstract][Full Text] [Related]
17. Cyclo-oxygenase-2 inhibition increases blood pressure in rats.
Höcherl K; Endemann D; Kammerl MC; Grobecker HF; Kurtz A
Br J Pharmacol; 2002 Aug; 136(8):1117-26. PubMed ID: 12163344
[TBL] [Abstract][Full Text] [Related]
18. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
[TBL] [Abstract][Full Text] [Related]
19. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation.
Wallace JL; Chapman K; McKnight W
Br J Pharmacol; 1999 Mar; 126(5):1200-4. PubMed ID: 10205009
[TBL] [Abstract][Full Text] [Related]
20. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis.
Jacoby RF; Seibert K; Cole CE; Kelloff G; Lubet RA
Cancer Res; 2000 Sep; 60(18):5040-4. PubMed ID: 11016626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
